title: [Outcomes of using autologous peripheral-blood stem cells in patients with chronic lower arterial insufficiency].
abstract: Presented herein are the outcomes of using autologous peripheral blood stem cells (SCs) in patients with stage II В lower limb chronic obliterating diseases (according to A.V. Pokrovsky's classification). Autologous SCs had previously been stimulated by means of the recombinant granulocytic colony stimulating factor (G-CSF) for five days. On day six, we performed mobilization of the peripheral blood stem cells on the MSC+ unit by means of leukopheresis followed by intramuscular administration of half of the obtained dose into the affected extremity. The mean number of the transplanted mononuclears amounted to 6.73 ± 2.2 x 10(9) cells, with the number of CD34+ cells averaging 2.94 ± 2.312 x 10(7). Assessing the therapeutic outcomes at 3 and 6 months of follow-up showed a statistically significant increase in the ankle-brachial pressure index (ABPI) [being at baseline 0.59 ± 0.04, at 3 months - 0.66 ± 0.04 (P=0.001), and after 6 months - 0.73 ± .08 (P=0.035)], accompanied and followed by improved measures of the treadmill test, with the pain-free walking distance at baseline equalling 102.2 ± 11.55 m, after 3 months - 129 ± 11.13 m (P<0.001), and after 6 months - 140 ± 13.11 m=0.021 vs baseline). The findings of the immunohistochemical study confirmed the development of neoangiogenesis in the skeletal muscle and a 25 percent increase in the capillary-network density following administration of autologous stem cells into the muscle. The method of transplanting peripheral-blood autologous stem cells for treatment of patients presenting with distal forms of chronic obliterating insufficiency of the lower limbs proved safe and efficient. The findings obtained during this study made it possible to recommend extending the indications for its application at the expense of patients with critical ischaemia.
authors: A V
authors: AV
authors: Maksimov
authors: A P
authors: AP
authors: Kiiasov
authors: M V
authors: MV
authors: Plotnikov
authors: S D
authors: SD
authors: Maianskaia
authors: I I
authors: II
authors: Shamsutdinova
authors: I M
authors: IM
authors: Gazizov
authors: M O
authors: MO
authors: Mavlikeev
mesh_terms: D000328:Adult; D055109:Ankle Brachial Index; D001772:Blood Cell Count; D016903:Drug Monitoring; D005080:Exercise Test; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D006801:Humans; D007273:Injections, Intramuscular; D035002:Lower Extremity / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D058729:Peripheral Arterial Disease / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D012039:Regional Blood Flow / Q000187:drug effects*; D012720:Severity of Illness Index; D014182:Transplantation, Autologous / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D016179:Granulocyte Colony-Stimulating Factor